… with immunomodulatory agents … immunomodulating agents, including neutralizing monoclonal
antibodies, corticosteroids, and other molecules in the management of severe COVID-19, …

… be considered as a potential therapeutic target against severe COVID-19. Consequently,
the proposal to treat severe COVID-19 with immunomodulatory therapy as it is done in HPS is …

… The aim of this project was to elaborate EULAR points to consider (PtCs) on COVID-19
pathophysiology and immunomodulatory therapies from the rheumatology perspective through a …

… Although few patients with severe COVID-19 would meet criteria for MAS, it is proposed that
they are on the spectrum and that MAS or secondary HLH therapies might be of benefit. IL-1 …

… for COVID-19. Finally, understanding the immunopathology of COVID-19 exclusively in T
cell-mediated immunity and the effects of cell-based immunomodulation therapies is …

… COVID-19. Corticosteroids are among the most commonly used drugs for immunomodulatory
therapy of … However, the use of corticosteroids in the treatment of COVID-19 can cause host …

… The aim of this project was to update the EULAR points to Consider (PtC) on the use of
immunomodulatory therapies in COVID-19 from the rheumatology perspective through a …

… ) in COVID-19. We report the emergency use of immunomodulatory therapy utilizing an …
)-6 levels and refractory COVID-19 ARDS requiring extracorporeal membrane oxygenation (…

… immunomodulatory therapies have emerged as a promising avenue for mitigating the challenges
posed by COVID-19… analyzes immunomodulatory interventions in managing COVID-19…

… Administration-approved COVID-19-specific therapies. Faced with rapidly increasing rates
of infection and hospitalizations, physicians repurposed immunomodulatory treatments in an …